Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Black patients with alopecia areata showed an average 20% reduction in scalp involvement after JAK inhibitor therapy, indicating positive treatment outcomes in this group.

This study observed that public interest in JAK-inhibitor treatments for alopecia areata significantly increased around the FDA approval in 2022 and heightened media coverage, suggesting an important role for patient education about these treatments.

This case report suggests that tofacitinib may effectively manage symptoms of AGS7 in a patient with an IFIH1 mutation, though further studies are needed to confirm its long-term safety and efficacy.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

In this analysis, JAK inhibitors were found to provide clinically meaningful and durable hair regrowth in pediatric alopecia areata, outperforming traditional therapies with a manageable safety profile.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

The authors highlighted promising developments in JAK inhibitors as targeted treatments for skin diseases such as atopic dermatitis, psoriasis, and alopecia areata, noting their effectiveness and safety profiles. Recent advances also suggest potential for treating melanoma with these inhibitors.

In this case report, a 9-year-old with alopecia areata experienced full hair regrowth after six months of oral tofacitinib, with no recurrence or significant side effects for a year post-treatment.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

This study found that Enz_MoriL, a compound derived from Morus alba L., promotes hair follicle cell proliferation by affecting the Wnt/β-catenin pathway and can counteract an alopecia areata-like condition by suppressing the JAK-STAT signaling in human hair follicle dermal papilla cells.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This paper reviews the autoimmune disorder alopecia areata, its progression, and its significant emotional and psychological impact, but reports no new clinical findings.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This report highlights that a coherent vision and collaboration are needed in Poland to address healthcare workforce shortages, including allowing domestic academic titles to confirm Polish language proficiency.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

In this study, patients with alopecia areata displayed altered scalp microbiota compared to healthy controls, and treatment with JAK kinase inhibitors largely restored these microbial changes, providing insights into the potential role of the skin microbiome in alopecia areata.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.

This study analyzed screening data from 218 alopecia areata patients before starting Janus kinase inhibitors, revealing the importance of pre-treatment screening due to risks of infections like tuberculosis and hepatitis B, with 74.8% of patients proceeding to treatment in real-world settings.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

In this review, the authors noted that while baricitinib, a treatment for refractory rheumatoid arthritis and severe alopecia areata, shows promising efficacy, it may pose risks of serious infections and malignancy due to immune downregulation.